COMPARISON OF  MUTANT P53 PROTEIN EXPRESSION  IN PTERYGIUM GROUP WITH AND WITHOUT TRIAMCINOLONE ACETONITED INJECTION

Background: Mutant p53 protein is produced by mutant p53 gene, this protein takes part in tissue hyperplasia process in pterygium. Triamcinolone acetonide in often use to reduce reccurency. Besides decreasing the inflamation triamcinolone acetonide is assumed to be able to repair the function of p53 gene. Thus, it reactivates cell apoptosis system and prevent the tissue hyperplasia process in pterygium.To compare Mutant p53 Protein Expression in Pterygium Group With and Without Triamcinolone Acetonide InjectionMethods: This research is a randomized clinical trial study consists of 31 subject who suffered primary pterygium. All subject divided into 2 grup with and without triamcinolone acetonide injection. After excision the pterygium and the tissue were examined through histopatology and immunohistochemical with Hematcoycline Eosin and reagent Clone DO7 staining to see the mutant p53 protein expression.Results: Mutant p53 protein expression in triamcinolone acetonite injected group is 0% and non triamcinolone acetonite injected group is 33,33%Conclusion: Mutant p53 protein expression in triamconolone acetonite injected group is lower than non injected grou. Keywords: Mutant p53 protein, primary pterygium, triamcinolone acetonide immunohistochemicial

Download Full-text

COMPARISON OF MUTANT P53 PROTEIN EXPRESSION IN PTERYGIUM GROUP WITH AND WITHOUT TRIAMCINOLONE ACETONITED INJECTION

Jurnal Ilmu Kesehatan Masyarakat ◽

10.26553/jikm.2018.9.3.171-178 ◽

2018 ◽

Vol 9 (3) ◽

pp. 171-178

Author(s):

Riani Erna

Keyword(s):

Clinical Trial ◽

Protein Expression ◽

Randomized Clinical Trial ◽

Triamcinolone Acetonide ◽

Cell Apoptosis ◽

P53 Protein ◽

P53 Gene ◽

Mutant P53 ◽

P53 Protein Expression ◽

Primary Pterygium

Download Full-text

Abstract 2962: Molecular mechanisms underlying the sensitizing effect of mutant p53 protein expression for Auranofin treatment of NSCLC and PDAC cells

10.1158/1538-7445.am2020-2962 ◽

2020 ◽

Author(s):

Laurie Freire Boullosa ◽

Filip Lardon ◽

Evelien Smits ◽

Christophe Deben

Keyword(s):

Protein Expression ◽

Molecular Mechanisms ◽

P53 Protein ◽

Mutant P53 ◽

P53 Protein Expression ◽

Sensitizing Effect

Download Full-text

Correlation of mutant P53 protein expression and Ki67 index with tumor response to concurrent chemoradiation in locally advanced head and neck cancer

Annals of Oncology ◽

10.1093/annonc/mdw363.64 ◽

2016 ◽

Vol 27 ◽

pp. vi36

Author(s):

P.B. Shanmuga ◽

K.T. Bhowmik ◽

K. Periasamy

Keyword(s):

Head And Neck Cancer ◽

Protein Expression ◽

Head And Neck ◽

Tumor Response ◽

P53 Protein ◽

Locally Advanced ◽

Mutant P53 ◽

Advanced Head ◽

Ki67 Index ◽

P53 Protein Expression

Download Full-text

Radiation Enhances the Anti-tumor Effects of Vaccinia-p53 Gene Therapy in Glioma

Technology in Cancer Research & Treatment ◽

10.1177/153303460300200306 ◽

2003 ◽

Vol 2 (3) ◽

pp. 223-235 ◽

Cited By ~ 12

Author(s):

Tatyana M. Timiryasova ◽

Daila S. Gridley ◽

Bing Chen ◽

Melba L. Andres ◽

Radha Dutta-Roy ◽

...

Keyword(s):

Protein Expression ◽

P53 Protein ◽

P53 Gene ◽

Immunohistochemical Analysis ◽

Live Cells ◽

C6 Cells ◽

Rat Glioma ◽

Combination Treatments ◽

P53 Protein Expression ◽

Single Modality

The overall goal of this study was to analyze the effect and mechanism of radiation in combination with vaccinia viruses (VV) carrying the p53 gene against glioma. Comparison of two alternative treatments of cultured C6 (p53+) and 9L (p53−) rat glioma cells showed significantly reduced survival for both cell lines, especially 9L, when radiation was applied prior to virus versus radiation alone. High p53 protein expression mediated by VV-TK-p53 was measured in infected cells. Single modality treatment of C6 cells with psoralen and UV (PUV)-inactivated VV-TK-p53 (PUV-VV-TK-53) or radiation significantly decreased survival compared with PUV-inactivated L-15 (PUV-L-15) control virus. However, no difference was observed between radiation and combination treatments of C6 cells. In contrast, radiation followed by PUV-VV-TK-53 resulted in dramatic reduction of 9L cell viability, compared to single modality treatment. Flow cytometry analysis of Annexin-V-stained 9L cells showed that radiation and PUV-VV-TK-53 caused a significant decrease in live cells (17.2%) as compared to other treatments and control (61.6–98.3%). Apoptosis was observed in 37.2% of cells, while the range was 0.7–7.8% in other treatment groups; maximal p53 level was measured on day 7 post-infection. In athymic mice bearing C6 tumors, VV-TK-53 plus radiation in both single and multiple therapies resulted in significantly smaller tumors by day 30 compared to the agents given only once. Immunohistochemical analysis of tumor sections demonstrated p53 protein expression over 20 days after VV-TK-53 treatment. Analysis of blood and spleen cells of mice given multiple combination treatments showed significant splenomegaly, leukocytosis, and increased DNA synthesis and response to mitogen. Multiple combination treatments were also associated with significantly elevated natural killer and B cells in the spleen. There were no overt toxicities, although depression in red blood cell and thrombocyte parameters was noted. Collectively, the data demonstrate that radiation significantly improves the efficacy of VV-mediated tumor suppressor p53 therapy and may be a promising strategy for glioma treatment. Furthermore, the results support the conclusion that the mechanisms underlying the enhanced anti-tumor effect of combination treatment include apoptosis/necrosis and upregulation of innate immune defenses.

Download Full-text